Cocrystal Pharma, Inc., a biotechnology company, is focused on the discovery and development of antiviral therapeutic treatments for serious and / or chronic viral diseases. The company is headquartered in Bothell, Washington.
| Revenue (TTM) | 510,000 |
| Gross Profit (TTM) | $-5.05M |
| EBITDA | $-8.95M |
| Operating Margin | 0.00% |
| Return on Equity | -111.40% |
| Return on Assets | -48.70% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $0.46 |
| Price-to-Book | 3.29 |
| Price-to-Sales (TTM) | 92.45 |
| EV/Revenue | 0.71 |
| EV/EBITDA | 0.66 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 26.90% |
| Shares Outstanding | $13.79M |
| Float | $9.12M |
| % Insiders | 32.83% |
| % Institutions | 5.59% |
Volatility is currently expanding